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Enoxaparin  sodium,  a  low-molecular-weight  heparin  (LMWH)  prepared  from  porcine  intestinal  heparin,
is widely  used  for the  prevention  and  treatment  of  venous  thromboembolism.  The  antithrombotic  activity
of heparin  is mediated  mainly  through  its activation  of  antithrombin  (AT) and  subsequent  inhibition  of
coagulation  factors.  Heparin  is a complex  heteropolymer  and  the  sulfation  pattern  of its  alternating  uronic
acid  and  glucosamine  sugar  units  is a major  factor  inﬂuencing  its  biological  activity.  The  manufacturing
process  itself  is  associated  with  the introduction  of  exogenous  microheterogeneities  that  may  further
affect  its biological  efﬁcacy.  This is important  since  enoxaparin  is prepared  by  depolymerizing  the  heparin
with  the aim  of optimizing  its  biological  activity  and  safety.  Changes  during  its manufacture  could  thus
affect  its biological  activity  and  safety.  The  current  study  was  performed  to assess  potential  differences
between  the  originator  enoxaparin  and  a new  generic  enoxaparin  commercialized  by  Teva.  Heparinase
digestion,  AT  afﬁnity  chromatography,  gel permeation  chromatography,  anion  exchange  chromatogra-
phy,  and  nuclear  magnetic  resonance  methodologies  were  used.  The  results  indicated  differences  in
oligosaccharides  related  to the  cleavage  selectivity  around  the  heparin  AT-binding  sequences of  the Teva
Enoxaparin  Sodium  Injection,  USP  and  the originator  Sanoﬁ  enoxaparin.  These  differences  inﬂuence  the
strength  of the  AT-binding  afﬁnity  of the  individual  oligosaccharides,  their  ability  to  activate  AT and,
therefore,  the inhibitory  potency  on  the  proteases  of the  coagulation  cascade.  This  study,  together  with
other  published  analytical  reports,  describes  speciﬁc  compositional  differences  between  generics  and
originator  LWMHs.  However,  it is yet  to be established  whether  such  variations  might  have any  clinical
relevance.
© 2016  The  Author(s).  Published  by Elsevier  B.V.  This  is  an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Enoxaparin sodium, a low-molecular-weight heparin (LWMH)
repared from United States Pharmacopeia (USP)-grade heparin
odium, is generally used as an anticoagulant for the preven-
ion and treatment of venous thromboembolism. Heparin is a
ighly sulfated linear heteropolymer composed of alternating units
Abbreviations: AT, antithrombin; BSA, bovine serum albumin; CTA,
etyltrimethylammonium; Gal, galactose; GlcA, glucuronic acid; LMWH, low-
olecular-weight heparin; NMR, nuclear magnetic resonance; SAX, strong anion
xchange; USP, United States Pharmacopeia.
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.0/).of uronic acids (-l-iduronic acid or -d-glucuronic acid) and
D-glucosamines. The latter sugar residues may  be N-sulfated, N-
acetylated, or O-sulfated at position 6, and less frequently, at
position 3. The uronic-acid residues can be O-sulfated at posi-
tion 2, although this is far more unusual for glucuronic acid
than for iduronic acid. The sulfation pattern responsible for these
microheterogeneities in heparin has an impact on its pleiotropic
effects and interaction with hundreds of proteins and enzymes
[1].
The antithrombotic activity of heparin is mediated mainly
through the activation of antithrombin (AT) [2] and the forma-
tion of ternary complexes with coagulation factors, principally
factors Xa and IIa [3]. Rare 3-O  sulfation moieties present on the
d-glucosamine residues are responsible for the speciﬁc binding of
heparin to AT [4,5]. The endogenous structure of heparin can, how-
ever, be partially denatured by chemical side reactions that may
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Nomenclature
U Uronic acid
IdoA l-Iduronic acid: -l–Idopyranosyluronic acid
U 4,5-Unsaturated uronic acid, e.g. GlcA: 4-deoxy-
-l-threo-hex-enepyranosyluronic acid
U2S Trisulfated disaccharide
2S 2-O-Sulfate
3S 3-O-Sulfate
6S 6-O-Sulfate
Structural Symbols
IVa U-GlcNAc
IVs U-GlcNS
IIa U-GlcNAc,6S
IIIa U  2S-GlcNAc
IIs U-GlcNS,6S
IIIs U  2S-GlcNS
Ia U  2S-GlcNAc,6S
Is U  2S-GlcNS,6S
IVsgal GalA-GlcNS
IIsgal GalA-GlcNS,6S
The iduronic (id) or glucuronic (glu) structure of uronic acids is
indicated for oligosaccharides. Underlined disaccharides have a
3-O-sulfated glucosamine
IIs U-GlcNS,3S,6S
Is U2S-GlcNS,3S,6S
IIsglu GlcA-GlcNS,3S,6S
IIa-IIsglu U-GlcNAc,6S- glcA-GlcNS,3S,6S
U  2S Percentage of oligosaccharides starting with 2-O
sulfated uronic acid
U Percentage of oligosaccharides starting with uronic
acid without 2-O  sulfation
NHAc 1 Acetyl group at the non-reducing end, on the ﬁrst
disaccharide building block
NHAc cent Acetyl group inside the oligosaccharide chain
NAc nbr/chain Number of acetyl groups per oligosaccharide
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ccur during the manufacturing process. Indeed, several chemical
teps required during the preparation of pure USP-grade heparin
ntroduce new, exogenous microheterogeneities that can act as a
ngerprint for the origin of the heparin [6].
Enoxaparin is prepared by the chemical depolymerization of
he heparin heteropolymer with the aim of optimizing its bio-
ogical activity and improving its efﬁcacy and safety proﬁle. The
noxaparin manufacturing process described in our previous work
odiﬁed the endogenous backbone through the introduction of
ew moieties, such as 1,6 anhydro bicyclic rings [7,8]. Brieﬂy,
he polysaccharide was esteriﬁed using benzyl ester and then
epolymerized by sodium hydroxide under appropriate operat-
ng conditions. The overall reaction conditions and the nature of
he depolymerizing base determine the structure and amounts
f the speciﬁc sequences generated, as well as the biological
ctivity proﬁle of the end product. Signiﬁcant changes such as
he choice of the base, e.g. a phosphazene base, were shown
o change the pharmacologic activity of the resulting product
9].
The ﬁrst two US-approved [10] generic enoxaparins pro-
uced by Sandoz and Amphastar were compared with the Sanoﬁ
riginator enoxaparin in 2015. Two studies, the ﬁrst based on high-
erformance liquid chromatography (HPLC) [11] and the second on
uclear magnetic resonance (NMR) [12], indicated that the genericd Biomedical Analysis 129 (2016) 542–550 543
enoxaparins showed speciﬁc differences when compared to the
originator. The use of compositional building block analysis [6,13]
was sufﬁcient to distinguish generic enoxaparins from the origina-
tor.
To study the Enoxaparin Sodium injection, USP by Amphastar
and Sandoz, methodologies and analytical procedures such as
AT afﬁnity chromatography, gel permeation chromatography
(GPC), and cetyltrimethylammonium–strong anion exchange (CTA-
SAX) chromatography were used [11]. The structural differences
between the generic and originator compounds were more pro-
nounced than would have been expected in any batch-to-batch
variations likely to occur during manufacture of biological prod-
ucts. These differences were statistically signiﬁcant and permitted
to distinguish between the generic enoxaparins produced by the
two manufacturers.
Other methods of analysis, the majority based on a single chro-
matographic separation followed by mass spectroscopy analysis
[14–18], have been proposed as suitable for the characterization of
LMWHs, however, these methods may  not be sufﬁcient since they
do not include any AT afﬁnity chromatography step, which sup-
plements the process with a key additional orthogonal resolving
power.
In February 2015, an Enoxaparin Sodium Injection, USP Teva
was launched in the US market. The current study compares the
structure of the Teva generic enoxaparin with the originator Sanoﬁ
compound using identical methodologies as those used previ-
ously to study the Amphastar and Sandoz generic enoxaparins
[11].
Our study also includes data on semuloparin. Semuloparin is an
experimental ultra-LMWH. Its development was stopped in 2012.
The inclusion of the semuloparin data is not intended as a compar-
ison with the enoxaparin compounds. Instead semuloparin is used
as an analytical reference, as extensive structural studies conducted
with semuloparin identiﬁed many AT binding oligosaccharides.
Therefore, semuloparin data are intended as a HPLC reference for
identiﬁcation of oligosaccharides and a NMR  reference for detection
of important characteristic signals.
2. Materials and methods
2.1. Materials
Two  samples of the Enoxaparin Sodium Injection, USP Teva
manufactured by Italfarmaco, AB 14023, expiry date 12–2017 (T1)
and AB 15027, expiry date 02-2018 (T2), were purchased in the USA
as preﬁlled syringes. A batch of Sanoﬁ enoxaparin, EEA 1412E (S1),
in powder form was  used as the reference enoxaparin for this com-
parability exercise (S1 was  one of the batches used in the previous
Amphastar and Sandoz study [11]). Semuloparin was also obtained
from Sanoﬁ (Vitry-sur-Seine, France). Heparinase I (EC 4.2.7), hep-
arinase II (no EC number), and heparinase III (EC 4.2.2.8) from
Flavobacterium heparinum were obtained from Grampian Enzymes
(Orkney, UK). All other reagents and chemicals were of the high-
est quality available. Water was  puriﬁed using a Millipore Milli-Q
puriﬁcation system (Darmstadt, Germany).
2.2. Exhaustive depolymerization using the heparinase mixture
(disaccharide building block analysis)
Enoxaparin samples were digested in the heparinase mixture
as described previously [6,11]. Brieﬂy, enoxaparin samples (20 l
of a 20 mg/ml  solution in water) were digested at room temper-
ature for 48 h in a total volume of 170 l containing 20 l of a
mixture of heparinase I, II, and III. Each heparinase was at 0.5
IU/ml in a potassium phosphate buffer (pH 7.0; 10 mM KH2PO4 and
544 P.A.J. Mourier et al. / Journal of Pharmaceutical an
Fig. 1. Gel permeation chromatography (GPC) chromatograms of (A) high-afﬁnity
and  (B) low-afﬁnity enoxaparin. Detected using a refractometer (blue lines: S1, red
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egend, the reader is referred to the web version of this article.)
.2 mg/ml  of bovine serum albumin [BSA]) and 120 l of sodium
cetate buffer (pH 7.0; 100 mM)  containing Ca(OAc)2 (2 mM)  and
SA (0.5 mg/ml) [6]. Digested samples were then injected onto a
olumn (250 × 3.2 mm)  ﬁlled with Spherisorb SAX of 5 m parti-
le diameter (Waters, Guyancourt, France) using chromatographic
onditions previously described [6].
.3. Direct chromatographic analysis of the enoxaparin batches
oligosaccharide sequence analysis)
The procedure used for purposes of the oligosaccharide
equence analysis was identical to that previously described for
tudying Amphastar and Sandoz generic enoxaparins [11]. Brieﬂy,
wo injections of 100 mg  of each of the enoxaparin digests were
eparated using an AT-sepharose column (30 cm × 7 cm)  [19]. The
esulting desalted high- and low-afﬁnity fractions were injected
nto a column (100 cm × 2.6 cm)  ﬁlled with Bio Gel P-30 (Bio-
ad, Marnesla-Coquette, France) and eluted as previously described
11]. Examples of GPC chromatograms of high- and low-afﬁnity
noxaparins are shown in Fig. 1. All of the fractions smaller than
etradecasaccharides were desalted and lyophilized. The fractions
ere then ready for further analysis, using either chromatography
r nuclear magnetic resonance (NMR).
The chromatographic analysis of fractions was  performed
referentially using CTA-SAX chromatography [20] as describedd Biomedical Analysis 129 (2016) 542–550
previously [11] or using a Carbopack AS11 column (250 × 2.1-mm;
Thermo Scientiﬁc Dionex, Villebon sur Yvette, France) [21]. Both
methods used UV transparent mobile phases allowing dual UV
detection of the eluted fractions at 232 nm and at the N-acetylated
speciﬁc signal at 202–242 nm.  The N-acetylated oligosaccharide
signal is the result of subtracting the 202 nm UV wavelength signal
from the 247 nm reference signal [11,21].
2.4. NMR
Enoxaparin fractions were prepared by dissolving 2–5 mg  of
sample in 0.6 ml  D2O with sodium phosphate buffer 10 mM
adjusted to pH 7.2 (Euriso-Top, Saint-Aubin, France). The NMR
spectra were recorded at 600 MHz  on an Avance 600 spectrome-
ter (Bruker BioSpin, Wissembourg, France) equipped with a 5 mm
Triple Resonance (TXI) cryoprobe at a temperature of 25 ◦C, with
pre-saturation of the residual water signals and with full recycle
delay of 7.4 s 2D heteronuclear single quantum correlation (HSQC)
spectra were recorded with carbon decoupling during acquisi-
tion, using phase-sensitive echo/antiecho time proportional phase
incrementation (TPPI) gradient selection (Bruker BioSpin standard
sequence library). The polarization transfer delay was  calculated
with a 1JCH coupling value of 145 Hz. Experiments were zero-
ﬁlled and multiplied with appropriate sine-bell apodization prior
to Fourier transformation.
2.5. Data processing
The weight/weight (w/w)  percentages of the building blocks
for each of the enoxaparin batches were quantiﬁed [22,23]. The
calculations were performed according the following formula [6]:
Component i % (w/w) = 100 × Mwi × Ai∑
xMwx × Ax
Mwi and Ai are the molecular weight and the chromatographic area
at 232 nm of the assayed component i, respectively. Mwx and Ax are
the molecular weight and the chromatographic area, respectively,
of either the peak X or the zone X speciﬁed by its retention time;
the sum being related to all the eluted components.
3. Results and discussion
3.1. Analysis of the disaccharide building blocks
The results of the disaccharide building block analysis, follow-
ing exhaustive heparinase digestion and SAX chromatography, are
provided in Table 1S and Fig. 1S (Supplementary data). The main
observation was the lower content in both the generic T1 and T2
batches of building blocks related to the reducing end (Glyserox1
and IVa) [10]. The 1,6-anhydro content of the T1 and T2 batches
was found to be compliant with the USP and National Formulary
(USP–NF) enoxaparin monograph [24].
3.2. CTA-SAX chromatograms of the enoxaparins
The CTA-SAX chromatograms of the enzymes digest batches “as
they are” in Fig. 2A did not reveal major differences between the
Sanoﬁ and the Teva enoxaparin batches. Differences were, how-
ever, present in the chromatograms of the AT high-afﬁnity fractions
as shown in Fig. 2B. The oligosaccharide size distribution of the
T1 and T2 batches was characterized by the presence of a higher
content of smaller oligosaccharides. This difference correlated with
the GPC chromatogram proﬁle of the same high-afﬁnity fractions
shown in Fig. 1A.
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Fig. 2. Cetyltrimethylammonium–strong anion exchange (CTA-SAX) chro-
matograms of the originator Sanoﬁ enoxaparin S1 and the generic Teva T1 and T2
enoxaparin batches (A) “as they are” and (B) their high afﬁnity fractions (black
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Fig. 3. Cetyltrimethylammonium–strong anion exchange (CTA-SAX) chro-
matograms of the originator Sanoﬁ enoxaparin S1 and the generic Teva T1
and T2 enoxaparin batches (black line: UV 232 nm,  red line: UV  202–242 nm).
(A) High-afﬁnity octasaccharides and (B) High-afﬁnity decasaccharides o1:
Is-IIaid-IIsglu-IIIsid; o2: IIa-IIsglu-Isid-Isid1,6anhydro; o3: IIa-IIsglu-Isid-Isid;
o4: IIa-IIsglu-Isid-Isidepi; o5: Is-IIaid-IIsglu-Isid1,6anhydro; o6: Is- IIaid-
IIsglu-Isid1,6anhydro−epi; o7: Is-IIaid-IIsglu-Isid. d1: IIa-IVsglu-Isid-Isid-Isid; d2:
IIa-IIsglu-Isid-Isid-IIsglu; d3: IIa-IIsglu-Isid-Isid-Isid; d4: Is-IIaid-IIsglu-Isid-Isid;
d5:  Is-IIaid-IIsglu-Isid-Isid1,6anhydro; d6: Is-Isid-IIaid-IIsglu-Isid. (For interpretation
of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)ine: UV 232 nm,  red line: UV 202–242 nm). (For interpretation of the references to
olour in this ﬁgure legend, the reader is referred to the web  version of this article.)
The next step was fractionation of the whole AT high-afﬁnity
raction on the basis of oligosaccharide size. Each size-deﬁned
igh-afﬁnity fraction obtained after GPC puriﬁcation was compared
sing CTA-SAX. Differences were already detected in the high-
fﬁnity hexasaccharides (Supplementary data S.2.2.) and further
nalysis of the higher fraction sizes provided additional information
oncerning the nature of the discrepancies.
The CTA-SAX chromatograms of the main constituents of the
igh-afﬁnity octasaccharides and decasaccharides present in the
hree enoxaparin batches are shown in Figs. 3A and B. The
resence of supplementary non-endogenous derivatives in the
noxaparins, such as 1,6-anhydro derivatives, mannose epimers,
nd odd oligosaccharides, increased the complexity of the decasac-
haride mixture and were not fully resolved by any method.Following the structural identiﬁcation of the main high afﬁnity
octasaccharides in Fig. 3A, two  groups can be distinguished. The
AT high-afﬁnity pentasaccharide was  on the reducing side of the
chain in o1, o5, o6, and o7 in the ﬁrst group but on the non-reducing
side in o2, o3, and o4 in the second group. The ﬁrst group is the
major one present in enoxaparin as a result of the selectivity of the
depolymerization conditions. This observation can be summarized
as shown below:
5 ical and Biomedical Analysis 129 (2016) 542–550
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There are two ways to depolymerize the polysaccharide back-
one. Cleavage by the base at positions 2 will yield octasaccharides
ith pentasaccharide sequence at the reducing end. Cleavage at
ositions 3 will yield octasaccharides with pentasaccharides at the
on-reducing end. The cleavage in the AT core-binding domains at
osition 1 generates non-afﬁne oligosaccharides.
The selectivity of the cleavage is inﬂuenced by the stereo-
lectronic effect of the base, its nucleophilicity, and the reaction
onditions (anhydrous media) as introduced in Section 1. In 2009,
e demonstrated that particular bases, such as phosphazene
25,26], could depolymerize the heparin benzyl ester in a differ-
nt fashion than that observed for enoxaparin. This resulted in
he preparation of new LMWHs, such as semuloparin [9]. In this
ase, the cleavage occurred predominantly at position 3, rather than
osition 2 as found in enoxaparin.
In the present study, the high-afﬁnity octasaccharides of the
riginator S1 enoxaparin were also found to occur as a result of
ore cleavage at position 2. Differences were, however, observed
or the generic T1 and T2 enoxaparins where increases in AT
igh-afﬁnity pentasaccharides were found at the non-reducing
nd, thus demonstrating a change of selectivity towards position
. For example, in Fig. 3A the ratio of o7/o3 (Is-IIaid-IIsglu-
sid/IIa-IIsglu-Isid-Isid, results of the cleavage at position 2 and
, respectively), was approximately 2 for the S1 enoxaparin but
nly about 1 for the T1 and T2 generics. Such a degree of
odiﬁcation of selectivity had not previously been observed in
noxaparin AT-binding fractions prepared from the Sanoﬁ S1
riginator product or from the Sandoz and Amphastar generic com-
ounds.
The same trend was seen for the high-afﬁnity decasaccharides
hown in Fig. 3B. In the case of the S1 originator enoxaparin, the d2
nd d3 components (where the AT-binding pentasaccharide lies
n the non-reducing side) were present in much lower amounts
han the d4, d5, and d6 components (where the pentasaccharide
s present in the middle or the reducing end of the chain). By con-
rast, the high-afﬁnity decasaccharides with AT-binding sites on
he non-reducing end (d2, d3) are present in much higher amounts
n the Teva T1 and T2 generic enoxaparins. This ﬁnding is con-
istent with the observations on the octasaccharides (Fig. 3A) and
emonstrates the presence of different depolymerization selectiv-
ties in the T1 and T2 enoxaparins compared with the Sanoﬁ S1
riginator enoxaparin. It should also be noted that the AT-binding
fﬁnity is increased for octasaccharides that have their pentasac-
harides located at the non-reducing end compared to those with
entasaccharides located at the reducing end. It was previously
emonstrated that the ﬂanking oligosaccharides played an impor-
ant role in the afﬁnity strength of the AT-pentasaccharide domain
27].3.3. AS11 SAX chromatograms of the enoxaparins
The same fractions assessed by CTA-SAX were analyzed using
the AS11 SAX method; results are shown in Figs. 4A and B. The selec-
tivity of the AS11 column is different to that of CTA-SAX. In contrast
to CTA-SAX, separation using the AS11 method bears more relation
to the number of sulfates present. This property is mostly indepen-
dent of their location within the oligosaccharide. The consequence
is that high-afﬁnity diacetylated oligosaccharides are more easily
detected by AS11 chromatography than by CTA-SAX where they
can be co-eluted with monoacetylated compounds. Diacetylated
oligosaccharides can be detected at twice of the signal the level of
monoacetylated oligosaccharides on AS11 chromatograms by the
molar ratio of the N-acetyl selective UV signal (202–242 nm in red)
compared to the oligosaccharide black signal (232 nm)  marker of
the unsaturated uronic acids. These compounds, despite their lower
content in the fractions, have biologic signiﬁcance because of a sec-
ond N-acetylated glucosamine, the presence of which signiﬁcantly
increases their afﬁnity for AT [27]. Fig. 4A shows that the levels of
the diacetylated high-afﬁnity octasaccharides were easily detected
and were higher in Teva T1 and T2 enoxaparins than in the Sanoﬁ
S1 enoxaparins. These octasaccharides have a similar structure to
IIa-IIsglu-Isid-IIaid (o9) in which the AT-binding site is at the non-
reducing end and the additional acetylated glucosamine is located
at the reducing end (Fig. 4).
Fig. 4B shows the presence of higher amounts of diacetylated
decasaccharides than in the octasaccharides fraction. The main
decasaccharide found in the S1 enoxaparin was d8 or Is-IIaid-
IIsglu-Isid-IIaid where the AT-binding site was located in the middle
of the chain. Chromatograms obtained from analyzing the T1 and
T2 samples show the presence and greater enrichment of other
diacetylated decasaccharides, such as d8, than those detected in
the S1 originator; their UV spectra, unlike d7, showed their unsat-
urated acid was 2-OH [22] (Supplementary data S.2.3.) and that the
AT-binding site was again present at the non-reducing site. Their
structure corresponded to the IIa-IIsglu-Isid-Isid-IIaid or IIa-
IIsglu-Isid-Iaid-IIsglu decasaccharides that were primarily present
in semuloparin [9,28] where the depolymerization occurred at
position 3. This was in contrast to S1 enoxaparin and favored
AT-binding sites located at the non-reducing end as described in
Section 3.2.
The CTA-SAX chromatograms of the high-afﬁnity dodecasac-
charides (Supplementary data, Fig. 3S) conﬁrmed the observations
from the high-afﬁnity octasaccharides and decasaccharides. The
IIa-IIsglu-Isid-Isid-Isid-Isid components were present in higher
quantities than Is-IIaid-IIsglu-Isid-Isid-Isid, Is-Isid-IIaid-IIsglu-
Isid-Isid, and Is-Isid-Isid-IIaid-IIsglu-Isid in the T1 and T2 samples
compared to the originator S1 enoxaparin. The chromatograms for
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Fig. 4. AS11 strong anion exchange chromatograms of Sanoﬁ enoxaparin S1, generic
Teva T1 and T2 enoxaparin batches and semuloparin (black line: UV 232 nm;
red  line: UV 202–242 nm). (A) High-afﬁnity octasaccharides and (B) High-afﬁnity
decasaccharides. o1: Is-IIaid-IIsglu-IIIsid, o2: IIa-IIsglu-Isid-Isid1,6anhydro, o3: IIa-
IIsglu-Isid-Isid; o4: IIa-IIsglu-Isid-Isidepi, o5: Is-IIaid-IIsglu-Isid1,6anhydro, o6: Is-
IIaid-IIsglu-Isid1,6anhydro−epi, o7: Is-IIaid-IIsglu-Isid, o8: Is-IIaid-IIsglu-Isidep, o9: IIa-
IIsglu-Isid-IIaid, d1: IIa-IVsglu-Isid-Isid-Isid, d2: IIa-IIsglu-Isid-Isid-IIsglu, d3: IIa-
IIsglu-Isid-Isid-Isid, d4: Is-IIaid-IIsglu-Isid-Isid, d5: Is-IIaid-IIsglu-Isid-Isid1,6anhydro,
d6:  Is-Isid-IIaid-IIsglu-Isid, d7: IIa-IIsglu-Isid-Isid-IIaid + IIa-IIsglu-Isid-Iaid-IIsglu,
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Fig. 5. Cetyltrimethylammonium–strong anion exchange (CTA-SAX) chro-
matograms of originator Sanoﬁ enoxaparin S1 and generic Teva T1 and T2
enoxaparin batches (black line: UV 232 nm, red line: UV 202–242 nm)  (A) tetrasac-
charides and (B) low-afﬁnity hexasaccharides. t1: Is-Isid1,6anhydro, t2: Is-Isglu,
t3:  Is-Isid, t4: Is-Isidepi , o4: IIa-IIsglu-Isid-Isidepi, h1: Is-Isid-IIsglu1,6anhydro, h2:
Is-Isid-IIsglu, h3: Is-Isid-Isid1,6anhydro, h4: Is-Isid-Isid, h5: Is-Isid-Isid epi. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred8: Is-IIaid-IIsglu-Isid-IIaid. (For interpretation of the references to colour in this
gure legend, the reader is referred to the web version of this article.)
he high-afﬁnity tetradecasaccharides (Supplementary data, Fig.
S) were too complex to be interpreted “as they are”.
No major differences were observed between the low-afﬁnity
ractions from the tetrasaccharide to octasaccharide obtained from
he Teva T1 and T2 batches and the originator S1 enoxaparin
Fig. 5 and Supplementary data S.2.2.). By contrast, differences
ere detected in the low-afﬁnity fractions of the decasaccharides
Supplementary data Fig. 7S). The proportions of the fully sul-
ated sequences (d7 and d8) were higher in the T1 and T2 Teva
atches than in the S1 enoxaparin. The same trend was also present
n the low-afﬁnity dodecasaccharides and tetradecasaccharides
Fig. 6). In addition, a lower content of oligosaccharides with anto the web  version of this article.)
oxidized glycoserine Glyserox residue at the reducing end was
clearly observed in both the T1 and T2 Teva batches. This result
is compatible with the lower content of Glyserox assayed in the
building blocks analysis for T1 and T2 (Supplementary data, Table
1S).
3.4. Statistical limitations of the HPLC studies
The height ratio of the representative AT binding peaks show-
ing deploymerization selectivity were shown and represent the
basis for the terms higher and lower used in the study. While the
lack of statistical analysis might be considered to constitute a lim-
itation, our previous rigorous analytical and statistical study [11]
has shown that the state of the art methodologies used here can
demonstrate reproducible statistical differences between different
batches of enoxaparins.
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Fig. 6. Cetyltrimethylammonium–strong anion exchange (CTA-SAX) chro-
matograms of originator Sanoﬁ enoxaparin S1 and generic Teva T1 and T2
enoxaparin batches (black line: UV 232 nm;  red line: UV 202–242 nm)  (A)
Low-afﬁnity dodecasaccharides and (B) tetradecasaccharides. dd1: Is-Isid-Isid-
Isid-Isid-Isid, dd2: Is-Isid-Isid-Isid-Isid-Isid1,6anhydro,dd3: Is-X-X-X-Glyserox),
td1: Is-Is -Is -Is -Is -Is -Is , td2: Is-Is -Is -Is -Is -Is -Is 1,6anhydro,td3:

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Is-X-X-X-X-Glyserox. (For interpretation of the references to colour in this ﬁgure
egend, the reader is referred to the web version of this article.)
.5. NMR
The NMR  studies provided quantitative data on the constituents
f the enoxaparin batches. The NMR 1H spectra of the enoxaparin
ethyl signal of the glucosamine acetyl groups are found between
.03 and 2.05 ppm. A signal in this region is typical of the presence
f acetyl groups located inside the oligosaccharide chains. How-
ver, when the acetyl moieties are located in the U-GlcNAc,6S
equence, which is characteristic of the cleavage at the position 3
ielding AT-binding sequences at the non-reducing end, the signal
s shifted to 2.06 ppm. As shown in Fig. 7, semuloparin was the only
1MWH which presented an intense signal at 2.06 ppm on the H
pectrum, due to the presence of the U-GlcNAc,6S sequence in the
T-binding sites as described in hexasaccharides [9], octasaccha-
ides [27], dodecasaccharides [29], and octadecasaccharides [21].Fig. 7. NMR H 600 MHz  spectra of anomeric and NAcetyl signals in high afﬁnity
fractions of originator Sanoﬁ enoxaparin S1 (upper part), generic Teva T1 (at the
middle) and semuloparin (bottom part).
Similarly, the proton signal of the double bond in U is located
at 5.8 ppm whereas the U2S proton signal is found at 5.95 ppm.
In comparison to the U2S signal, the U produced a particularly
intense signal in semuloparin when compared to S1 enoxaparin.
Since the majority of the AT afﬁne oligosaccharides had their bind-
ing site on the non-reducing side of the backbone, semuloparin
provides a good reference point for the assessment of the cleavage
selectivity at position 3 versus position 2 between the S1 and T1, T2
enoxaparins. Fig. 7 shows that the 2.06 ppm and 5.85 ppm signals
of the originator S1 enoxaparin were comparatively weak when
compared to those at 2.03–2.05 ppm and 5.95 ppm, respectively,
consistent with the selectivity observed with HPLC analysis. Con-
versely, the 2.06 ppm and 5.85 ppm signals were increased in the
Teva T1 and T2 enoxaparin NMR  spectra as shown in Fig. 7 referred
to above, a result that was  also compatible with the HPLC ﬁndings.
As a consequence of this, the NMR  spectra were measured for each
fraction and the respective percentages of U and U2S, as well
as U-GlcNAc,6S and U2S-GlcNAc,6S (U being an internal uronic
acid, either (IdoA2S or GlcA2S)) are summarized in Table 1. The
individual values indicate the low inter-batch variability between
the two different enoxaparin generic samples that were available
at the time of the study. The results were also compared with data
obtained from semuloparin further supporting the differences in
cleavage selectivity of heparin AT binding domain and the resulting
oligosaccharide compositional features.
4. Conclusions
The NMR  differences observed between the high AT afﬁnity frac-
tions of the Teva T1 and T2 batches and the originator enoxaparin
S1 were consistent with the initial observations obtained from the
chromatographic data. These results established that the location of
the AT-binding site in the oligosaccharide chains in the Teva batches
differed to that in the originator enoxaparin. The two Teva batches,
however, had a consistent composition to each other and exhibited
a high degree of identity. Despite this, the structural characteristics
of their high AT afﬁnity fractions, obtained using both chromato-
graphic and NMR  analyses, were found to be different from the
originator S1 enoxaparin.In our previous comparative study on enoxaparin generics [11],
we reported statistical differences in the composition of generic
versus originator enoxaparins and speciﬁc signatures associated
with the production process. Despite these ﬁndings, the cleav-
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Table  1
NMR 1H analytical comparison of high afﬁnity fractions from Sanoﬁ originator S1 enoxaparin, generic Teva T1 and T2 enoxaparin batches and Semuloparin: determination of
the  ratios between ethylenic protons of 2-O sulfated and 2-hydroxylated uronic acids and of the N-acetyl moieties location in U-GlcNAc vs internal U-GlcNAc sequences.
High-afﬁnity fractions Enoxaparin sample U 2OSO3− (%) U 2OH (%) NHAc 1 (%) NHAc cent (%) NHAc nbr/chain
Dp8 S1 63.7 36.3 39.4 60.6 0.99
T1  48.5 51.5 53.2 46.8 1.03
T2  49.0 51.0 52.0 48.0 0.98
Semuloparin 29.0 71.0 60.2 39.8 0.96
Dp10 S1 74.8 25.2 26.4 73.6 1.10
T1  60.0 40.0 34.0 66.0 1.16
T2  61.6 38.4 35.8 64.2 1.12
Semuloparin 36.2 63.8 42.1 57.9 1.23
Dp12 S1 78.1 21.9 14.5 85.5 1.28
T1  67.3 32.7 21.2 78.8 1.29
T2  68.0 32.0 23.5 76.5 1.22
Semuloparin 42.3 57.7 42.1 57.9 1.23
Dp14 S1 80.5 19.5 13.5 86.5 1.53
T1  71.2 28.8 20.9 79.1 1.45
T2  72.5 27.5 21.5 78.5 1.42
Semuloparin 44.9 55.1 26.0 74.0 1.76
Full  fraction S1 78.7 21.3 15.9 84.1 1.70
T1  67.8 32.2 25.5 74.5 1.56
T2  68.5 31.5 23.9 76.1 1.55
Semuloparin 36.1 63.9 42.8 57.2 1.25
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tp8, octasaccharide; Dp10, decasaccharide; Dp12, duodecasaccharide; Dp14, tetrasa
ronic acid 2-OH; NHAc1, NHAcetyl located in U-GlcNAc sequence; NHAc cent, N
ge conditions (nature of the base and reaction settings) had little
ffect on the cleavage selectivity within the AT domain of the hep-
rin starting material when compared to the originator enoxaparin.
ost probably, the depolymerization reactions setting were rather
imilar to the originator.
Despite those ﬁndings that also affected the AT-binding
equences (especially above decasaccharides), the base used in
hese processes was barely affecting the cleavage selectivity within
he AT domain of heparin starting material when compared to
he originator. In the current case, however, the depolymerization
onditions of the Teva generic and Sanoﬁ originator enoxaparin
amples appeared to differ and to exert an impact on the oligosac-
haride composition of each AT-binding fraction. In fact, the
eva T1 and T2 generic enoxaparins exhibited hybrid AT bind-
ng oligosaccharide proportions that lie between those of the
riginator enoxaparin and the analytical HPLC reference semu-
oparin. Furthermore they were enriched in oligosaccharides with
entasaccharides being located at the non-reducing end of the
equence as pointed out by characteristic signal of the NMR  ref-
rence semuloparin. Such differences inﬂuence the strength of
T-binding afﬁnity of the individual oligosaccharides [16] and,
herefore, their ability to activate AT.
In summary, we have observed that the Teva generic
noxaparins exhibit differences as compared to the originator
noxaparin. The type of difference between the Teva enoxaparin
nd the originator enoxaparins identiﬁed in the current study
learly show the potential need to include AT-afﬁnity chromatog-
aphy as a key step in the characterization of LMWHs. Despite the
ifferences attributed to the manufacturing processes, it is yet to
e established whether such variations might have any clinical rel-
vance.
onﬂict of interest
P. Mourier, F. Herman, P. Sizun, and C. Viskov are employees of
anoﬁ.ole of the funding source
The study was carried out by Sanoﬁ R&D employees as part of
heir research duties. All authors contributed to the drafting of the
[ide; U 2OSO3− , 4,5-unsaturated uronic acid 2-O-Sulfate; U2OH, 4,5-unsaturated
yl central; NHAc nbr/chain, number of NHAcetyl by chain.
manuscript with editorial assistance provided by a medical writer,
paid for by Sanoﬁ. The decision to submit the article for publication
was shared by all authors.
Acknowledgement
This study was funded by Sanoﬁ. Editorial support in the prepa-
ration of this article was provided by M. Calle, Excerpta Medica,
funded by Sanoﬁ.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jpba.2016.07.033.
References
[1] H.E. Conrad, Heparin-Binding Proteins, Academic Press, California, 1998.
[2] L. Thunberg, G. Bäckström, U. Lindahl, Further characterization of the
antithrombin-binding sequence in heparin, Carbohydr. Res. 100 (1982)
393–410.
[3] R.W. Colman, V.J. Marder, A.W. Clowes, J.N. George, S.Z. Goldhaber, Overview
of hemostasis, in: V.J. Colman, A.W. Marder, J.N. Clowes (Eds.), Hemostasis
and Thrombosis: Basic Principles and Clinical Practice, Lippincott Williams
and  Wilkins Philadelphia, Baltimore, New York, London, Buenos Aires, Hong
Kong, Sydney, and Tokyo, 2006, pp. 3–16.
[4] B. Casu, Structure and active domains of heparin, in: H.G. Garg, R.J. Linhardt,
C.A. Hales (Eds.), Chemistry and Biology of Heparin and Heparan Sulfate,
Elsevier Science, Amsterdam, 2005, pp. 1–28.
[5] B. Casu, U. Lindahl, Structure and biological interactions of heparin and
heparan sulfate, Adv. Carbohydr. Chem. Biochem. 57 (2001) 159–206.
[6] P. Mourier, P. Anger, C. Martinez, F. Herman, C. Viskov, Quantitative
compositional analysis of heparin using exhaustive heparinase digestion and
strong anion exchange chromotography, Anal. Chem. Res. 3 (2015) 46–53,
http://dx.doi.org/10.1016/j.ancr.2014.12.001.
[7] G. Mascellani, M.  Guerrini, G. Torri, L. Liverani, F. Spelta, P. Bianchini,
Characterization of di- and monosulfated unsaturated heparin disaccharides
with terminal N-sulfated 1 6-anhydro--D-glucosamine or N-sulfated
1,6-anhydro--D-mannosamine residues, Carbohydr. Res. 342 (2007)
835–842.
[8] P. Mourier, C. Viskov, Method for determining speciﬁc groups constituting
heparins or low molecular weight heparins, U.S. Patent 2005/0119477 A1,
Chem. Abstr. 142 (2005) 89363.
[9] C. Viskov, M.  Just, V. Laux, P. Mourier, M.  Lorenz, Description of the chemical
and  pharmacological characteristics of a new hemisynthetic
ultra-low-molecular-weight heparin, AVE5026, J. Thromb. Haemost. 7 (2009)
1143–1151, http://dx.doi.org/10.1111/j.1538-7836.2009.03447.x.
10]  P. Minghetti, F. Cilurzo, S. Franzé, U.M. Musazzi, M.  Itri, Low molecular weight
heparins copies: are they considered to be generics or biosimilars? Drug
5 ical an
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[50 P.A.J. Mourier et al. / Journal of Pharmaceut
Discov. Today 18 (2013) 305–311, http://dx.doi.org/10.1016/j.drudis.2012.11.
002.
11] P.A. Mourier, C. Agut, H. Souaiﬁ-Amara, F. Herman, C. Viskov, Analytical and
statistical comparability of generic enoxaparins from the US market with the
originator product, J. Pharm. Biomed. Anal. 115 (2015) 431–442, http://dx.doi.
org/10.1016/j.jpba.2015.07.038.
12] M.  Guerrini, T.R. Rudd, L. Mauri, E. Macchi, J. Fareed, E.A. Yates, A. Naggi, G.
Torri, Differentiation of generic enoxaparins marketed in the United States by
employing NMR  and multivariate analysis, Anal. Chem. 87 (2015) 8275–8283,
http://dx.doi.org/10.1021/acs.analchem.5b01366.
13] Z. Wang, D. Li, X. Sun, X. Bai, L. Jin, L. Chi, Liquid chromatography-diode array
detection-mass spectrometry for compositional analysis of low molecular
weight heparins, Anal. Biochem. 451 (2014) 35–41, http://dx.doi.org/10.1016/
j.ab.2014.02.005.
14] Q. Zhang, X. Chen, Z. Zhu, X. Zhan, Y. Wu,  L. Song, J. Kang, Structural analysis of
low molecular weight heparin by ultraperformance size exclusion
chromatography/time of ﬂight mass spectrometry and capillary zone
electrophoresis, Anal. Chem. 85 (2013) 1819–1827, http://dx.doi.org/10.1021/
ac303185w.
15] L. Li, F. Zhang, J. Zaia, R.J. Linhardt, Top-down approach for the direct
characterization of low molecular weight heparins using LC-FT–MS, Anal.
Chem. 84 (2012) 8822–8829, http://dx.doi.org/10.1021/ac302232c.
16]  G. Li, J. Steppich, Z. Wang, Y. Sun, C. Xue, R.J. Linhardt, L. Li, Bottom-up low
molecular weight heparin analysis using liquid chromatography–fourier
transform mass spectrometry for extensive characterization, Anal. Chem. 86
(2014) 6626–6632, http://dx.doi.org/10.1021/ac501301v.
17] S.N. Oliveira, G.R. Santos, B.F. Glauser, N.V. Capillé, I.N. Queiroz, M.S. Pereira,
V.H. Pomin, P.A. Mourão, Structural and functional analyses of biosimilar
enoxaparins available in Brazil, Thromb. Haemost. 113 (2015) 53–65, http://
dx.doi.org/10.1160/TH14-05-0411.
18] X. Xu, D. Li, L. Chi, X. Du, X. Bai, L. Chi, Fragment proﬁling of low molecular
weight heparins using reversed phase ion pair liquid
chromatography–electrospray mass spectrometry, Carbohydr. Res. 407
(2015) 26–33, http://dx.doi.org/10.1016/j.carres.2015.01.016.
19] M.  Höök, I. Björk, J. Hopwood, U. Lindahl, Anticoagulant activity of heparin:
separation of high-activity and low-activity heparin species by afﬁnity
chromatography on immobilized antithrombin, FEBS Lett. 66 (1976) 90–93,
http://dx.doi.org/10.1016/0014-5793(76)80592-3.
[d Biomedical Analysis 129 (2016) 542–550
20] P.A. Mourier, C. Viskov, Chromatographic analysis and sequencing approach
of heparin oligosaccharides using cetyltrimethylammonium dynamically
coated stationary phases, Anal. Biochem. 332 (2004) 299–313.
21] P.A. Mourier, O.Y. Guichard, F. Herman, C. Viskov, Isolation of a pure
octadecasaccharide with antithrombin activity from an
ultra-low-molecular-weight heparin, Anal. Biochem. 453 (2014) 7–15, http://
dx.doi.org/10.1016/j.ab.2014.02.013.
22] A. Pervin, C. Gallo, K.A. Jandik, X.J. Han, R.J. Linhardt, Preparation and
structural characterization of large heparin-derived oligosaccharides,
Glycobiology 5 (1995) 83–95.
23] K.G. Rice, R.J. Linhardt, Study of structurally deﬁned oligosaccharide
substrates of heparin and heparin monosulfate lyases, Carbohydr. Res. 190
(1989) 219–233.
24] U.S. Pharmacopeia–National Formulary (USP–NF), Test for
1,6-anhydroderivative for enoxaparin sodium, U.S. Pharmacopeial
Convention, 2009. http://www.usp.org/sites/default/ﬁles/usp pdf/EN/USPNF/
genChapter207.pdf (accessed 20.03.16).
25] R. Schwesinger, J. Willaredt, H. Schlemper, M.  Keller, D. Schmitt, H. Fritz,
Novel, very strong, uncharged auxiliary bases; design and synthesis of
monomeric and polymer-bound Triaminoiminophosphorane bases of broadly
varied steric demand, Chem. Ber. 127 (1994) 2435–2454, http://dx.doi.org/10.
1002/cber.19941271215.
26] R. Schwesinger, H. Schlemper, C. Hasenfratz, Extremely strong, uncharged
auxiliary bases; monomeric and polymer-supported polyaminophosphazenes
(P2–P5), Liebigs Ann. (1996) 1055–1081, http://dx.doi.org/10.1002/jlac.
199619960705.
27] M.  Guerrini, S. Guglieri, B. Casu, G. Torri, P. Mourier, C. Boudier, C. Viskov,
Antithrombin-binding octasaccharides and role of extensions of the active
pentasaccharide sequence in the speciﬁcity and strength of interaction.
Evidence for very high afﬁnity induced by an unusual glucuronic acid residue,
J.  Biol. Chem. 283 (2008) 26662–26675, http://dx.doi.org/10.1074/jbc.
M801102200.
28] V. Biberovic, L. Grondard, P. Mourier, C. Viskov, Mixture of sulfated
oligosaccharides, U.S. Patent (2011) 8003623 B2.29] C. Viskov, S. Elli, E. Urso, D. Gaudesi, P. Mourier, F. Herman, C. Boudier, B. Casu,
G.  Torri, M.  Guerrini, Heparin dodecasaccharide containing two
antithrombin-binding pentasaccharides: structural features and biological
properties, J. Biol. Chem. 288 (2013) 25895–25907, http://dx.doi.org/10.1074/
jbc.M113.485268.
